Device Trial Radar · NCT04683718
A First in Human Feasibility Study to Evaluate the Safety and Effectiveness of the BIOTRONIK Prospera SCS System With HomeStream Remote Management
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Sep 20, 2021
Primary completion
Aug 21, 2025
Study completion Oct 2029
Sponsor
- Lead sponsor
- Biotronik, Inc.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- Biotronik Australia Pty Ltd.; BIOTRONIK Neuro
- First posted
- Dec 24, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The BENEFIT-03 Clinical Study is a first in human, prospective, multi-center, single-arm, interventional feasibility study to be conducted in Australia. The purpose of the BENEFIT-03 study is to collect initial safety and effectiveness data on the BIOTRONIK Prosper SCS (Spinal Cord Stimulation) System with HomeStream Remote Management. Enrolled participants will complete a SCS trial period per the standard of care utilizing the BIOTRONIK Resilience percutaneous SCS trial leads and the BIOTRONIK Prospera External Pulse Generator (EPG). Following a successful trial period, participants will be implanted with a permanent BIOTRONIK Prospera Implantable Pulse Generator (IPG). Implanted participants will be followed for 24 months post-implant with in-office visits and remote management visits. For participants who consent to participate in an additional registry phase of the study, study follow-up will continue beyond 24 months with registry data collection up to 5 years post-implant.
Conditions
- Chronic Low-back Pain
- Chronic Leg Pain
Interventions
Permanent implant of a BIOTRONIK Prospera SCS (Spinal Cord Stimulation) System with HomeStream Remote ManagementDevice
The Prospera SCS System is a rechargeable, 16-electrode, MRI conditional Spinal Cord Stimulation system that delivers electrical stimulation to the dorsal column of the spinal cord for the treatment of chronic intractable pain of the trunk and/or limbs.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Responder Rate to the BIOTRONIK Prospera SCS System TherapyTime frame: 6 months post-implant
- Primary Safety Information on the BIOTRONIK Prospera SCS SystemTime frame: 6 months post-implant
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Genesis Research Services
Broadmeadow, New South Wales, Australia
Australian Medical Research
Hurstville, New South Wales, Australia
Sydney Pain Research Centre
Wahroonga, New South Wales, Australia
2 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.